{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:44:33Z","timestamp":1759333473514},"reference-count":48,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,1,15]]},"abstract":"<jats:p> PURPOSE: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin\u2019s lymphoma (PCNHL). <\/jats:p><jats:p> PATIENTS AND METHODS: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I. <\/jats:p><jats:p> RESULTS: We identified 46 patients, 27 males, with median age of 57 years. Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient. The complete response rate was 95%. After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma. The first failure was exclusively cutaneous in 50% of relapses. For the 44 treated patients, progression-free survival (PFS; actuarial \u00b1 SE) was 61% \u00b1 7% and survival was 58% \u00b1 9% at 12 years. For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71% \u00b1 12% (P = .0003) versus 0% after radiotherapy; survival was 77% \u00b1 12% versus 25% \u00b1 22% (P = 004), respectively. For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89% \u00b1 11% and survival 70% \u00b1 18%. <\/jats:p><jats:p> CONCLUSION: PCNHL is rare, and its first relapse is exclusively cutaneous in 50% of patients. Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy. Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy. <\/jats:p>","DOI":"10.1200\/jco.2001.19.2.398","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:36:55Z","timestamp":1487921815000},"page":"398-405","source":"Crossref","is-referenced-by-count":28,"title":["Primary Cutaneous Non-Hodgkin\u2019s Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy"],"prefix":"10.1200","volume":"19","author":[{"given":"Andreas H.","family":"Sarris","sequence":"first","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Braunschweig","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul S.","family":"Ha","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Cox","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma and Myeloma, Blood and Marrow Transplantation, Hematopathology, Dermatology, and Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-083738","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(86)90009-X"},{"key":"R2-083738","unstructured":"Willemze  R,   Kerl  H,   Sterry  W,  et al:  EORTC classification for primary cutaneous lymphomas:   A Proposal from the Cutaneous Lymphoma Study Group of the European Organization for the Research and Treatment of Cancer.   Blood 90:  354,1997-371,"},{"key":"R3-083738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.11.1994"},{"key":"R4-083738","unstructured":"Grange  F,   Hedelin  G,   Joly  P,  et al:  Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sezary syndrome:   The French Study Group on Cutaneous Lymphomas.   Blood 93:  3637,1999-3642,"},{"key":"R5-083738","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930315)71:6<2097::AID-CNCR2820710626>3.0.CO;2-7"},{"key":"R6-083738","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-3-199502010-00009"},{"key":"R7-083738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.539"},{"key":"R8-083738","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058833"},{"key":"R9-083738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.549"},{"key":"R10-083738","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910501)67:9<2311::AID-CNCR2820670918>3.0.CO;2-0"},{"key":"R11-083738","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30866-0"},{"key":"R12-083738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2080"},{"key":"R13-083738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2152"},{"key":"R14-083738","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008253426523"},{"key":"R15-083738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2471"},{"key":"R17-083738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R18-083738","unstructured":"Carbone  PP,   Kaplan  HS,   Musshoff  K,  et al:  Report of the Committee on Hodgkin\u2019s Disease Staging Classification.   Cancer Res 31:  1860,1971-1861,"},{"key":"R19-083738","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501440"},{"key":"R20-083738","doi-asserted-by":"crossref","unstructured":"Lee  L,   Cabanillas  FC,   Bodey  FP,  et al:  A 10-year update of CHOP-Bleo in the treatment of DLCL.   J Clin Oncol 4:  1455,1985-1461,","DOI":"10.1200\/JCO.1986.4.10.1455"},{"key":"R21-083738","unstructured":"Swan  FJ,   Velasquez  W,   Fuller  L,  et al:  Successful outcome of patients (pts) with good risk large cell lymphoma (LCL) with a shortened schedule of treatment (RX).   Proc Am Soc Clin Oncol 10:  947a,1991  (abstr)"},{"key":"R22-083738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2530"},{"key":"R23-083738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.117.117"},{"key":"R24-083738","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008214629544"},{"key":"R25-083738","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197603)37:3<1275::AID-CNCR2820370307>3.0.CO;2-M"},{"key":"R26-083738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.2.551.551"},{"key":"R27-083738","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058324"},{"key":"R28-083738","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010543"},{"key":"R29-083738","doi-asserted-by":"crossref","unstructured":"Miller  TP,   Jones  SE:   Chemotherapy of localized histiocytic lymphomas.   Lancet 1:  358,1979-360,","DOI":"10.1016\/S0140-6736(79)92894-0"},{"key":"R30-083738","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801201)46:11<2356::AID-CNCR2820461107>3.0.CO;2-X"},{"key":"R31-083738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.2.413.bloodjournal622413"},{"key":"R32-083738","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-1-25"},{"key":"R33-083738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1295"},{"key":"R34-083738","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S"},{"key":"R35-083738","unstructured":"Levitt  SH,   Bloomfield  CD,   Frizzera  G,  et al:  Curative radiotherapy for localized diffuse histiocytic lymphoma.   Cancer Treat Rep 64:  175,1980-177,"},{"key":"R36-083738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.6.1218.bloodjournal5861218"},{"key":"R37-083738","doi-asserted-by":"crossref","unstructured":"Kaminski  MS,   Coleman  CN,   Colby  TV,  et al:  Factors predicting survival in adults with stage I and II large cell lymphoma treated with primary radiation therapy.   Ann Intern Med 104:  746,1986-756,","DOI":"10.7326\/0003-4819-104-6-747"},{"key":"R38-083738","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I"},{"key":"R39-083738","unstructured":"Glick  JH,   Kim  K,   Earl  J:   An ECOG randomized phase III trial of CHOP vs CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin\u2019s lymphoma.   Proc Am Soc Clin Oncol 14:  391,1995  (abstr 1221)"},{"key":"R40-083738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390104"},{"key":"R41-083738","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198607000-00002"},{"key":"R42-083738","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1989.tb00875.x"},{"key":"R43-083738","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70090-2"},{"key":"R44-083738","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90337-9"},{"key":"R45-083738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.2.651.bloodjournal862651"},{"key":"R46-083738","unstructured":"Sarris  AH,   Daliani  D,   Ulmer  R,  et al:  Interferon-inducible protein-10 as a possible factor in the epidermotropism of cutaneous T-cell lymphomas.   Clin Cancer Res 3:  169,1997-177,"},{"key":"R47-083738","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809068568"},{"key":"R48-083738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.4.1423.bloodjournal8741423"},{"key":"R49-083738","unstructured":"Sarris  AH,   Talpaz  M,   Deisseroth  AB,  et al:  Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors.   Leukemia 10:  757,1996-765,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.2.398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:48:16Z","timestamp":1653515296000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.2.398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,15]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,1,15]]}},"alternative-id":["10.1200\/JCO.2001.19.2.398"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.2.398","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,15]]}}}